Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

ZIVO Bioscience (OTCMKTS:ZIVO) Stock Passes Above 50 Day Moving Average of $3.84

Defense World ·  {{timeTz}}

Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.84 and traded as high as $4.05. ZIVO Bioscience shares last traded at $3.75, with a volume of 15,356 shares.

ZIVO Bioscience Stock Performance

The firm has a market capitalization of $35.33 million, a price-to-earnings ratio of -3.79 and a beta of -0.04. The company has a 50-day moving average of $3.84 and a 200-day moving average of $3.59.

Get ZIVO Bioscience alerts:

ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.

Institutional Investors Weigh In On ZIVO Bioscience

A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. increased its holdings in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.04% of the company's stock.

ZIVO Bioscience Company Profile

(Get Rating)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Read More

  • Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.